BioNxt Solutions (TSE:BNXT) has released an update.
BioNxt Solutions Inc. has entered into a master services agreement with a German international contract research, development, and manufacturing organization to propel product development, focusing on their oral dissolvable drug formulations for the multiple sclerosis market. The partnership aims to streamline BioNxt’s path towards clinical studies and commercialization of their proprietary Cladribine dosage form, tapping into a market poised to grow significantly by 2033.
For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.
